Highlights Amicus Therapeutics, Inc.

Equities

FOLD

US03152W1099

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
10.43 ^USD	+4.40%		-1.04%	-26.50%

Mar. 18	JPMorgan Adjusts Price Target on Amicus Therapeutics to $19 From $21, Maintains Overweight Rating	MT
Mar. 05	Amicus Therapeutics Insider Sold Shares Worth $389,543, According to a Recent SEC Filing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Amicus Therapeutics Swings to Q4 Earnings, Revenue Rises	Feb. 28	MT
Earnings Flash (FOLD) AMICUS THERAPEUTICS Posts Q4 EPS $0.01, vs. Street Est of $-0.04	Feb. 28	MT
Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	Feb. 28	CI
Amicus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Amicus Therapeutics Sees Revenue Growth of 21% in 2023	Jan. 08	MT
Amicus Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	Jan. 07	CI
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight	Dec. 20	DJ
Amicus Therapeutics' Q3 Net Loss Narrows, Revenue Rises	Nov. 08	MT
Amicus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease	23-09-28	CI
New Paradigm Therapeutics, Inc. acquired worldwide rights of SD-101 from Amicus Therapeutics, Inc..	23-08-21	CI
Amicus Therapeutics Says Late-Onset Pompe Disease Therapy Approved by UK Healthcare Products Regulator	23-08-15	MT
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom	23-08-15	CI
Amicus Therapeutics Q2 Loss Narrows as Revenue Increases; Cuts 2023 Operating Expenses Outlook	23-08-08	MT
Amicus Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Amicus Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2023	23-08-08	CI
Amicus Therapeutics Inc. Announces Approval and Launch of New Pompe Disease Therapy in the European Union	23-06-27	CI
Amicus Therapeutics Q1 Loss Narrows as Revenue Rises; Company Reaffirms 2023 Operating Expenses Outlook	23-05-10	MT
Amicus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2023	23-05-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Amicus Therapeutics, Inc.

Equities

FOLD

US03152W1099

Highlights

Filters